PetVivo Holdings Inc. (PETV): Price and Financial Metrics
GET POWR RATINGS... FREE!
PETV Stock Summary
- For PETV, its debt to operating expenses ratio is greater than that reported by only 8.47% of US equities we're observing.
- With a price/sales ratio of 37.58, PETVIVO HOLDINGS INC has a higher such ratio than 95.69% of stocks in our set.
- As for revenue growth, note that PETV's revenue has grown 1,195.12% over the past 12 months; that beats the revenue growth of 99.23% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to PETVIVO HOLDINGS INC are PLAG, SIBN, ZOM, APYX, and MLSS.
- PETV's SEC filings can be seen here. And to visit PETVIVO HOLDINGS INC's official web site, go to www.petvivo.com.
PETV Valuation Summary
- In comparison to the median Healthcare stock, PETV's EV/EBIT ratio is 159.54% lower, now standing at -3.9.
- Over the past 104 months, PETV's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for PETV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PETV | 2023-03-17 | 37.5 | 40.6 | -3.9 | -3.9 |
| PETV | 2023-03-16 | 37.1 | 40.1 | -3.8 | -3.8 |
| PETV | 2023-03-15 | 38.7 | 41.8 | -4.0 | -4.0 |
| PETV | 2023-03-14 | 37.4 | 40.4 | -3.9 | -3.9 |
| PETV | 2023-03-13 | 38.7 | 41.8 | -4.0 | -4.0 |
| PETV | 2023-03-10 | 42.4 | 45.8 | -4.4 | -4.4 |
PETV Growth Metrics
- The 4 year net income to common stockholders growth rate now stands at 86.59%.
- The year over year revenue growth rate now stands at 818.95%.
- Its 2 year cash and equivalents growth rate is now at 57609.57%.
The table below shows PETV's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 0.847023 | -6.869724 | -8.165398 |
| 2022-09-30 | 0.387918 | -6.584401 | -7.495909 |
| 2022-06-30 | 0.169615 | -5.620795 | -6.489794 |
| 2022-03-31 | 0.115586 | -4.174957 | -5.014995 |
| 2021-12-31 | 0.065401 | -3.075964 | -3.561249 |
| 2021-09-30 | 0.014904 | -1.915159 | -2.956873 |
PETV Stock Price Chart Interactive Chart >
PETV Price/Volume Stats
| Current price | $3.04 | 52-week high | $3.60 |
| Prev. close | $2.97 | 52-week low | $1.23 |
| Day low | $3.00 | Volume | 16,800 |
| Day high | $3.07 | Avg. volume | 36,611 |
| 50-day MA | $2.80 | Dividend yield | N/A |
| 200-day MA | $2.37 | Market Cap | 32.92M |
PetVivo Holdings Inc. (PETV) Company Bio
PetVivo Holdings, Inc. is a veterinary biotech and biomedical device company. It is engaged in the business of translating or adapting human biotech and medical technology into products for commercialization in the veterinary market to treat companion animals such as dogs, horses, cats, and other animals suffering from osteoarthritis and other afflictions. The firm's lead product includes Kush, is an intra-articular injection comprised of patented, gel-like biomaterials that is being commercialized for companion animal osteoarthritis. The company was founded by John Lai and John F. Dolan on March 31, 2009 and is headquartered in Minneapolis, MN.
Latest PETV News From Around the Web
Below are the latest news stories about PETVIVO HOLDINGS INC that investors may wish to consider to help them evaluate PETV as an investment opportunity.
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, MontanaMINNEAPOLIS, MN, US, March 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Erik Kleemam DVM, MPH, of Ethos Veterinary Health presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benef |
PetVivo Holdings, Inc. to Exhibit and Dr. Erik Kleeman of Ethos Veterinary Health to Present Canine Study Results at the Veterinary Orthopedic Society Annual ConferenceMINNEAPOLIS, MN, US, March 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced today it will be exhibiting at the Veterinary Orthopedic Society (“VOS”) annual conference to be held March 11th to Marth 18th, 2023 at the Yellowstone Conference Center in Big Sky, Montana. PetVivo intends to exhibit i |
New to The Street Announces the Televised Lineups for Shows 441, 442, and 443, Airings on Three Networks Will Begin on Saturday, February 25, 2023, 3:30 PM ETNew to The Street Announces the Televised Lineups for Shows 441, 442, and 443, Airings on Three Networks begins on Saturday, February 25, 2023, 3:30 PM ET Televised Lineups for Shows 441, 442, and 443: 1). Tocvan Ventures Corp. (OTCQB: TCVNF) (CSE: TOC) (FSE: TV3) ($TCVNF) 2). PetVivo Holdings, Inc. (NASDAQ: PETV) (NASDAQ: PETVW) ($PETV) 3). OiginClear, Inc. (OTC: OCLN) ($OCLN) 5). Avenir Wellness Solutions, Inc. (f/k/a - CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) ($CURR) 6). Hempacco Co., |
PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE WESTERN VETERINARY CONFERENCE IN LAS VEGAS, NEVADAMINNEAPOLIS, Feb. 13, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held February 19th to February 22nd, 2023 at the Mandalay Bay Convention Center in Las Vegas, Nevada. PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, an intra-arti |
PetVivo Holdings, Inc. (NASDAQ:PETV) Q3 2023 Earnings Call TranscriptPetVivo Holdings, Inc. (NASDAQ:PETV) Q3 2023 Earnings Call Transcript February 9, 2023 John Dolan: Greetings, and welcome to the PetVivo Holdings Third Quarter of Fiscal Year 2023 Financial Results Conference Call. My name is John Dolan, the Chief Business Development Officer and General Counsel at PetVivo. Today’s call is being webcast and will be posted […] |
PETV Price Returns
| 1-mo | N/A |
| 3-mo | 48.66% |
| 6-mo | 59.16% |
| 1-year | 10.55% |
| 3-year | 105.41% |
| 5-year | -51.49% |
| YTD | 55.11% |
| 2022 | -48.01% |
| 2021 | -71.55% |
| 2020 | 578.79% |
| 2019 | N/A |
| 2018 | 0.00% |
Loading social stream, please wait...